


Viral Epidemiology Snapshot: July 31-August 6, 2022


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV					
<u>Virus</u>	#Tested	#Positive	% Positive		
Flu A	230	2	0.9%		
Flu B	230	0	0.0%		
RSV	224	15	6.7%		
CoV-2 PUI	873	192	22.0%		
CoV-2 Surveillance	450	19	4.2%		

Flu A Subtyping				
2009 H1N1	0			
Seasonal H1	0			
Seasonal H3	2			
No Subtype	0			
Pending subtype	0			

Other Respiratory Viruses					
<u>Virus</u>	#Tested	#Positive	% Positive		
Adenovirus	220	17	7.7%		
Coronavirus 229E	220	0	0.0%		
Coronavirus HKU1	220	0	0.0%		
Coronavirus NL63	220	0	0.0%		
Coronavirus OC43	220	0	0.0%		
Metapneumovirus	220	0	0.0%		
Rhinovirus/Enterovirus	220	50	22.7%		
Parainfluenza 1	220	5	2.3%		
Parainfluenza 2	220	1	0.5%		
Parainfluenza 3	220	6	2.7%		
Parainfluenza 4	220	2	0.9%		





This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of Feb. '22) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as "no subtype".

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line ("PUI") shows data for all patients with symptoms or known exposures ("Patient Under Investigation") while the purple line ("Surv.") shows surveillance data for undergoing pre-procedure screening.

As of Oct. '21, the surveillance line shows patients who have been designated as "pre-procedure" in their testing order questionnaire, as well as participants in the employee screening program.